Bristol-Myers Squibb Company announced today that the USFDA approved the use of REYATAZ (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected patients.
The details can be read here.
No comments:
Post a Comment